These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 31483988

  • 1. Exacerbations, Health Resource Utilization, and Costs Among Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease Treated with Nebulized Arformoterol Following a Respiratory Event.
    Navaie M, Celli BR, Xu Z, Cho-Reyes S, Dembek C, Gilmer TP.
    Chronic Obstr Pulm Dis; 2019 Oct 23; 6(4):297-307. PubMed ID: 31483988
    [Abstract] [Full Text] [Related]

  • 2. Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment.
    Celli BR, Navaie M, Xu Z, Cho-Reyes S, Dembek C, Gilmer TP.
    Int J Chron Obstruct Pulmon Dis; 2019 Oct 23; 14():1019-1031. PubMed ID: 31190787
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Predictors of Nebulized Arformoterol Treatment: A Retrospective Analysis of Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease.
    Gilmer TP, Celli BR, Xu Z, Cho-Reyes S, Dembek C, Navaie M.
    COPD; 2019 Apr 23; 16(2):140-151. PubMed ID: 31215259
    [Abstract] [Full Text] [Related]

  • 5. Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting β2-agonists.
    Chen YJ, Makin C, Bollu VK, Navaie M, Celli BR.
    J Med Econ; 2016 Apr 23; 19(1):11-20. PubMed ID: 26357881
    [Abstract] [Full Text] [Related]

  • 6. Treatment Transitions in Chronic Obstructive Pulmonary Disease: Retrospective Analyses of US and UK Healthcare Databases.
    Bloom CI, Montonen J, Jöns O, Garry EM, Bhatt SP.
    Pulm Ther; 2022 Mar 23; 8(1):75-93. PubMed ID: 35015269
    [Abstract] [Full Text] [Related]

  • 7. Hospital and emergency department utilization associated with treatment for chronic obstructive pulmonary disease in a managed-care Medicare population.
    Simoni-Wastila L, Yang HW, Blanchette CM, Zhao L, Qian J, Dalal AA.
    Curr Med Res Opin; 2009 Nov 23; 25(11):2729-35. PubMed ID: 19778165
    [Abstract] [Full Text] [Related]

  • 8. Association between incidence of acute exacerbation and medication therapy in patients with COPD.
    Suh DC, Lau H, La HO, Choi IS, Geba GP.
    Curr Med Res Opin; 2010 Feb 23; 26(2):297-306. PubMed ID: 19961283
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers.
    Singer D, Bengtson LGS, Elliott C, Buikema AR, Franchino-Elder J.
    Int J Chron Obstruct Pulmon Dis; 2020 Feb 23; 15():3239-3250. PubMed ID: 33324047
    [Abstract] [Full Text] [Related]

  • 11. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
    Simoni-Wastila L, Blanchette CM, Qian J, Yang HW, Zhao L, Zuckerman IH, Pak GH, Silver H, Dalal AA.
    Am J Geriatr Pharmacother; 2009 Oct 23; 7(5):262-70. PubMed ID: 19948302
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
    Spencer S, Evans DJ, Karner C, Cates CJ.
    Cochrane Database Syst Rev; 2011 Oct 05; (10):CD007033. PubMed ID: 21975759
    [Abstract] [Full Text] [Related]

  • 15. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM, Akazawa M, Dalal A, Simoni-Wastila L.
    Am J Geriatr Pharmacother; 2008 Aug 05; 6(3):138-46. PubMed ID: 18775388
    [Abstract] [Full Text] [Related]

  • 16. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
    Blais L, Forget A, Ramachandran S.
    Clin Ther; 2010 Jul 05; 32(7):1320-8. PubMed ID: 20678680
    [Abstract] [Full Text] [Related]

  • 17. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
    Kew KM, Mavergames C, Walters JA.
    Cochrane Database Syst Rev; 2013 Oct 15; 2013(10):CD010177. PubMed ID: 24127118
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Differences in health care outcomes between postdischarge COPD patients treated with inhaled corticosteroid/long-acting β2-agonist via dry-powder inhalers and pressurized metered-dose inhalers.
    Wittbrodt ET, Millette LA, Evans KA, Bonafede M, Tkacz J, Ferguson GT.
    Int J Chron Obstruct Pulmon Dis; 2019 Oct 15; 14():101-114. PubMed ID: 30613140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.